Sirona Biochem Corp. Logo

Sirona Biochem Corp.

SRBCF

(1.8)
Stock Price

0,06 USD

-329.51% ROA

90.17% ROE

-7.87x PER

Market Cap.

20.440.689,55 USD

-95.82% DER

0% Yield

16294.87% NPM

Sirona Biochem Corp. Stock Analysis

Sirona Biochem Corp. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Sirona Biochem Corp. Fundamental Stock Analysis
# Analysis Rating
1 ROE

The stock's ROE exceeds expectations (14187.61%), revealing strong profitability and efficient use of shareholders' equity, making it an attractive investment opportunity.

2 PBV

The stock's low PBV ratio (-22.34x) suggests it's undervalued, making it an attractive opportunity for investors.

3 DER

The stock has a minimal amount of debt (-190%) relative to its ownership, showcasing a strong financial position and lower risk for investors.

4 Assets Growth

Company's revenue has experienced consistent growth over the last three years, indicating a favorable financial trajectory and making it an attractive investment choice.

5 ROA

The stock's ROA (-152.74%) indicates that it's not effectively utilizing its assets to generate profits, making it a less favorable option to invest and earn consistent returns.

6 Revenue Growth

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

7 Net Profit Growth

This company's net profit has remained flat over the past five years, suggesting a lack of growth and making it a less attractive investment opportunity.

8 Graham Number

The Graham number calculation reveals that this company's stock price is potentially inflated, implying that it may not be a desirable investment option.

9 Dividend Growth

The company's dividend growth has shown no improvement in the past three years, making it a less attractive investment option for those seeking increasing returns.

10 Dividend

The company's lack of dividends in the past three years may concern investors seeking regular income.

11 Buffet Intrinsic Value

The company's stock presents a potential concern as it appears overvalued (0) by Warren Buffett's formula, indicating that its market price exceeds its estimated intrinsic value.

Sirona Biochem Corp. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Sirona Biochem Corp. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Buy
3 RSI Hold
4 Stoch RSI Buy

Sirona Biochem Corp. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Sirona Biochem Corp. Revenue
Year Revenue Growth
2006 0
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 207.737 100%
2015 7.995 -2498.34%
2016 360.500 97.78%
2017 5.468 -6492.9%
2018 1.278.695 99.57%
2019 135.743 -842%
2020 105.711 -28.41%
2021 268.022 60.56%
2022 671.923 60.11%
2023 238.056 -182.25%
2023 34.779 -584.48%
2024 10.172 -241.91%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Sirona Biochem Corp. Research and Development Expenses
Year Research and Development Expenses Growth
2006 0
2007 0 0%
2008 0 0%
2009 732.639 100%
2010 373.847 -95.97%
2011 799.721 53.25%
2012 478.101 -67.27%
2013 544.149 12.14%
2014 599.728 9.27%
2015 1.298.507 53.81%
2016 1.304.480 0.46%
2017 998.663 -30.62%
2018 946.919 -5.46%
2019 1.264.404 25.11%
2020 1.308.928 3.4%
2021 1.153.967 -13.43%
2022 1.079.740 -6.87%
2023 1.925.620 43.93%
2023 1.657.020 -16.21%
2024 1.833.984 9.65%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Sirona Biochem Corp. General and Administrative Expenses
Year General and Administrative Expenses Growth
2006 0
2007 238.591 100%
2008 129.454 -84.31%
2009 490.952 73.63%
2010 693.380 29.19%
2011 1.396.994 50.37%
2012 2.541.617 45.04%
2013 2.077.353 -22.35%
2014 3.083.317 32.63%
2015 2.206.656 -39.73%
2016 1.989.956 -10.89%
2017 1.496.617 -32.96%
2018 1.018.738 -46.91%
2019 2.859.654 64.38%
2020 2.600.774 -9.95%
2021 1.075.428 -141.84%
2022 2.672.895 59.77%
2023 980.688 -172.55%
2023 930.412 -5.4%
2024 797.724 -16.63%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Sirona Biochem Corp. EBITDA
Year EBITDA Growth
2006 -6
2007 -238.065 100%
2008 -129.454 -83.9%
2009 -1.223.591 89.42%
2010 -1.067.227 -14.65%
2011 -2.093.178 49.01%
2012 -2.898.878 27.79%
2013 -2.517.966 -15.13%
2014 -3.448.778 26.99%
2015 -3.283.592 -5.03%
2016 -2.784.709 -17.92%
2017 -2.303.990 -20.86%
2018 -911.980 -152.64%
2019 -4.443.550 79.48%
2020 -4.119.580 -7.86%
2021 -2.279.126 -80.75%
2022 -3.522.181 35.29%
2023 -3.020.584 -16.61%
2023 -2.852.910 -5.88%
2024 -2.649.228 -7.69%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Sirona Biochem Corp. Gross Profit
Year Gross Profit Growth
2006 0
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 -47.415 100%
2014 150.513 131.5%
2015 -204.915 173.45%
2016 309.882 166.13%
2017 5.468 -5567.19%
2018 1.278.695 99.57%
2019 135.743 -842%
2020 51.572 -163.21%
2021 199.250 74.12%
2022 621.755 67.95%
2023 238.056 -161.18%
2023 25.070 -849.57%
2024 10.172 -146.46%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Sirona Biochem Corp. Net Profit
Year Net Profit Growth
2006 -6
2007 -218.125 100%
2008 -97.082 -124.68%
2009 -1.215.771 92.01%
2010 -1.069.650 -13.66%
2011 -2.505.659 57.31%
2012 -2.983.286 16.01%
2013 -2.784.595 -7.14%
2014 -3.525.675 21.02%
2015 -3.546.142 0.58%
2016 -2.974.767 -19.21%
2017 -4.460.394 33.31%
2018 -1.273.246 -250.32%
2019 -4.549.575 72.01%
2020 -4.133.724 -10.06%
2021 -2.306.335 -79.23%
2022 -3.557.804 35.18%
2023 -3.055.644 -16.43%
2023 -2.543.190 -20.15%
2024 -3.540.716 28.17%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Sirona Biochem Corp. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2006 0
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2023 0 0%
2024 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Sirona Biochem Corp. Free Cashflow
Year Free Cashflow Growth
2006 -6
2007 -84.776 99.99%
2008 -123.558 31.39%
2009 -1.152.496 89.28%
2010 -842.703 -36.76%
2011 -2.569.771 67.21%
2012 -2.217.877 -15.87%
2013 -2.615.875 15.21%
2014 -2.094.758 -24.88%
2015 -2.911.134 28.04%
2016 -2.239.288 -30%
2017 -2.674.468 16.27%
2018 -653.801 -309.06%
2019 -3.559.490 81.63%
2020 -2.159.074 -64.86%
2021 -2.158.227 -0.04%
2022 -2.177.512 0.89%
2023 -759.558 -186.68%
2023 -1.757.512 56.78%
2024 -552.590 -218.05%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Sirona Biochem Corp. Operating Cashflow
Year Operating Cashflow Growth
2006 -6
2007 -84.776 99.99%
2008 -115.397 26.54%
2009 -1.151.203 89.98%
2010 -842.703 -36.61%
2011 -2.522.626 66.59%
2012 -2.144.535 -17.63%
2013 -2.607.206 17.75%
2014 -1.859.780 -40.19%
2015 -2.584.021 28.03%
2016 -2.103.256 -22.86%
2017 -2.498.852 15.83%
2018 -653.801 -282.2%
2019 -3.559.490 81.63%
2020 -2.112.104 -68.53%
2021 -2.158.227 2.14%
2022 -2.177.512 0.89%
2023 -759.558 -186.68%
2023 -1.757.512 56.78%
2024 -552.590 -218.05%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Sirona Biochem Corp. Capital Expenditure
Year Capital Expenditure Growth
2006 0
2007 0 0%
2008 8.161 100%
2009 1.293 -531.17%
2010 0 0%
2011 47.145 100%
2012 73.342 35.72%
2013 8.669 -746.03%
2014 234.978 96.31%
2015 327.113 28.17%
2016 136.032 -140.47%
2017 175.616 22.54%
2018 0 0%
2019 0 0%
2020 46.970 100%
2021 0 0%
2022 0 0%
2023 0 0%
2023 0 0%
2024 0 0%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Sirona Biochem Corp. Equity
Year Equity Growth
2006 99.995
2007 1.134.220 91.18%
2008 1.033.184 -9.78%
2009 479.692 -115.38%
2010 684.085 29.88%
2011 2.705.050 74.71%
2012 1.700.056 -59.12%
2013 2.239.334 24.08%
2014 1.790.301 -25.08%
2015 2.348.130 23.76%
2016 1.563.174 -50.22%
2017 -2.040.582 176.6%
2018 -2.260.966 9.75%
2019 2.189.537 203.26%
2020 47.395 -4519.76%
2021 -97.015 148.85%
2022 214.515 145.23%
2023 -827.854 125.91%
2023 -2.511.365 67.04%
2024 -3.463.968 27.5%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Sirona Biochem Corp. Assets
Year Assets Growth
2006 99.995
2007 1.182.944 91.55%
2008 1.081.483 -9.38%
2009 530.981 -103.68%
2010 963.245 44.88%
2011 3.432.306 71.94%
2012 2.676.483 -28.24%
2013 3.487.397 23.25%
2014 3.427.967 -1.73%
2015 4.746.184 27.77%
2016 3.125.047 -51.88%
2017 1.251.038 -149.8%
2018 770.510 -62.36%
2019 4.256.895 81.9%
2020 2.137.239 -99.18%
2021 1.287.464 -66%
2022 1.290.709 0.25%
2023 1.395.354 7.5%
2023 1.032.073 -35.2%
2024 809.176 -27.55%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Sirona Biochem Corp. Liabilities
Year Liabilities Growth
2006 0
2007 48.724 100%
2008 48.299 -0.88%
2009 51.289 5.83%
2010 279.160 81.63%
2011 727.256 61.61%
2012 976.427 25.52%
2013 1.248.063 21.76%
2014 1.637.666 23.79%
2015 2.398.054 31.71%
2016 1.561.873 -53.54%
2017 3.291.620 52.55%
2018 3.031.476 -8.58%
2019 2.067.358 -46.64%
2020 2.089.844 1.08%
2021 1.384.479 -50.95%
2022 1.076.194 -28.65%
2023 2.223.208 51.59%
2023 3.543.438 37.26%
2024 4.273.144 17.08%

Sirona Biochem Corp. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
-0
Net Income per Share
-0.01
Price to Earning Ratio
-7.87x
Price To Sales Ratio
-1249.2x
POCF Ratio
-10.36
PFCF Ratio
-10.09
Price to Book Ratio
-6.06
EV to Sales
-1450.03
EV Over EBITDA
-9.34
EV to Operating CashFlow
-11.72
EV to FreeCashFlow
-11.72
Earnings Yield
-0.13
FreeCashFlow Yield
-0.1
Market Cap
0,02 Bil.
Enterprise Value
0,02 Bil.
Graham Number
0.06
Graham NetNet
-0.01

Income Statement Metrics

Net Income per Share
-0.01
Income Quality
0.76
ROE
0.9
Return On Assets
-3.3
Return On Capital Employed
1.62
Net Income per EBT
0.92
EBT Per Ebit
1.14
Ebit per Revenue
155.3
Effective Tax Rate
0.08

Margins

Sales, General, & Administrative to Revenue
-63.3
Research & Developement to Revenue
-82.13
Stock Based Compensation to Revenue
-11.51
Gross Profit Margin
1.45
Operating Profit Margin
155.3
Pretax Profit Margin
176.66
Net Profit Margin
162.95

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-0.01
Free CashFlow per Share
-0.01
Capex to Operating CashFlow
0
Capex to Revenue
0
Capex to Depreciation
0
Return on Invested Capital
16.23
Return on Tangible Assets
-3.3
Days Sales Outstanding
-17123.93
Days Payables Outstanding
39850.13
Days of Inventory on Hand
0
Receivables Turnover
-0.02
Payables Turnover
0.01
Inventory Turnover
0
Capex per Share
0

Balance Sheet

Cash per Share
0,00
Book Value per Share
-0,01
Tangible Book Value per Share
-0.01
Shareholders Equity per Share
-0.01
Interest Debt per Share
0.01
Debt to Equity
-0.96
Debt to Assets
4.1
Net Debt to EBITDA
-1.29
Current Ratio
0.34
Tangible Asset Value
0,00 Bil.
Net Current Asset Value
0,00 Bil.
Invested Capital
-1567993
Working Capital
0,00 Bil.
Intangibles to Total Assets
0
Average Receivables
0,00 Bil.
Average Payables
0,00 Bil.
Average Inventory
0
Debt to Market Cap
0.16

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Sirona Biochem Corp. Dividends
Year Dividends Growth

Sirona Biochem Corp. Profile

About Sirona Biochem Corp.

Sirona Biochem Corp., a cosmetic ingredient and drug discovery company, develops and sells cosmetic and pharmaceutical active ingredients in Canada and France. Its programs include cosmetic skin lightener and diabetes drug; and other projects include the development of an anti-aging/cell protection library, novel anti-wrinkle compound, and anti-viral program. Sirona Biochem Corp. has a research collaboration agreement with the International Centre for Genetic Engineering and Biotechnology (ICGEB) to develop antiviral library of compounds. The company was formerly known as High Rider Capital Inc. and changed its name to Sirona Biochem Corp. in May 2009. The company was incorporated in 2006 and is headquartered in Vancouver, Canada.

CEO
Dr. Howard J. Verrico M.D., Ph
Employee
0
Address
595 Burrard Street
Vancouver, V7X 1L4

Sirona Biochem Corp. Executives & BODs

Sirona Biochem Corp. Executives & BODs
# Name Age
1 Dr. Howard J. Verrico M.D., Ph.D.
Founder, Chairman of the Board, Chief Executive Officer & Secretary
70
2 Mr. Christopher D. Hopton C.G.A., CPA
Chief Financial Officer & Director
70
3 Dr. GĂ©raldine Deliencourt-Godefroy Ph.D.
Chief Scientific Officer & Director
70

Sirona Biochem Corp. Competitors